Dianthus Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	6.24	2.83	6.42	1.48
Revenue Growth (YoY)	120.63%	-55.96%	334.76%	-
Gross Profit	6.24	2.83	6.42	1.48
Selling, General & Admin	24.99	18.16	6.74	1.96
Research & Development	83.11	32.84	29.38	12.61
Operating Expenses	108.1	51	36.12	14.56
Operating Income	-101.86	-48.17	-29.71	-13.09
Interest & Investment Income	17.37	4.76	1.15	0
Currency Exchange Gain (Loss)	-0.06	-0.09	0.14	-0.03
Other Non Operating Income (Expenses)	-0.55	-0.06	-0.05	-
EBT Excluding Unusual Items	-85.12	-43.56	-28.48	-13.11
Gain (Loss) on Sale of Investments	0.15	-	-	-
Pretax Income	-84.97	-43.56	-28.48	-13.11
Net Income	-84.97	-43.56	-28.48	-13.11
Net Income to Common	-84.97	-43.56	-28.48	-13.11
Shares Outstanding (Basic)	33	5	1	4
Shares Outstanding (Diluted)	33	5	1	4
Shares Change (YoY)	546.44%	489.48%	-78.17%	-
EPS (Basic)	-2.55	-8.45	-32.57	-3.27
EPS (Diluted)	-2.55	-8.45	-32.57	-3.27
Free Cash Flow	-78.29	-36.97	-29.21	-9.94
Free Cash Flow Per Share	-2.35	-7.17	-33.41	-2.48
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1633.75%	-1704.67%	-462.91%	-886.59%
Profit Margin	-1362.78%	-1541.22%	-443.76%	-888.14%
Free Cash Flow Margin	-1255.57%	-1308.24%	-455.18%	-673.24%
EBITDA	-101.77	-48.11	-29.68	-
D&A For EBITDA	0.1	0.07	0.03	-
EBIT	-101.86	-48.17	-29.71	-13.09
Revenue as Reported	6.24	2.83	-	-

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q